Cargando…
What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality
In this issue of EMBO Molecular Medicine, Uribesalgo and coworkers show that high Apelin expression correlates with poor survival in advanced breast (MMTV‐NeuT) and lung (KRAS (G12D)) murine tumor models as well as in breast and lung cancer in humans. Combining Apelin inhibition (genetically or usin...
Autor principal: | Claesson‐Welsh, Lena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685083/ https://www.ncbi.nlm.nih.gov/pubmed/31318171 http://dx.doi.org/10.15252/emmm.201910892 |
Ejemplares similares
-
Blood vessels as targets in tumor therapy
por: Claesson-Welsh, Lena
Publicado: (2012) -
Fighting vessel dysmorphia to improve glioma chemotherapy
por: Lohela, Marja, et al.
Publicado: (2017) -
Bad vessels beware! Semaphorins will sort you out!
por: Serini, Guido, et al.
Publicado: (2015) -
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013) -
Co‐targeting driver pathways in prostate cancer: two birds with one stone
por: Zoubeidi, Amina, et al.
Publicado: (2018)